New Horizons. A New Paradigm for Treating to Target with Second-Generation Obesity Medications
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
New Horizons. A New Paradigm for Treating to Target with Second-Generation Obesity Medications
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Volume -, Issue -, Pages -
Publisher
The Endocrine Society
Online
2021-12-05
DOI
10.1210/clinem/dgab848
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity
- (2021) Steven B. Heymsfield et al. JAMA Network Open
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity
- (2021) Thomas A. Wadden et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
- (2021) Melanie Davies et al. LANCET
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- (2021) John P.H. Wilding et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity
- (2021) Domenica Rubino et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial
- (2021) Lone B Enebo et al. LANCET
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
- (2021) Julio Rosenstock et al. LANCET
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
- (2021) Juan P. Frías et al. NEW ENGLAND JOURNAL OF MEDICINE
- CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2020 EXECUTIVE SUMMARY
- (2020) Alan J. Garber et al. Endocrine Practice
- Cardiometabolic-Based Chronic Disease, Adiposity and Dysglycemia Drivers
- (2020) Jeffrey I. Mechanick et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Proposal for a Scientifically Correct and Medically Actionable Disease Classification System (ICD) for Obesity
- (2020) W. Timothy Garvey et al. Obesity
- SELECT (Semaglutide effects on cardiovascular outcomes in people with overweight or obesity) rationale and design
- (2020) Donna H. Ryan et al. AMERICAN HEART JOURNAL
- Development and validation of a model for predicting incident type 2 diabetes using quantitative clinical data and a Bayesian logistic model: A nationwide cohort and modeling study
- (2020) Lua Wilkinson et al. PLOS MEDICINE
- 6. Glycemic Targets: Standards of Medical Care in Diabetes—2021
- (2020) DIABETES CARE
- 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
- (2019) Donna K. Arnett et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report
- (2019) Alison B. Evert et al. DIABETES CARE
- MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency
- (2018) Karine Clément et al. NATURE MEDICINE
- 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
- (2017) Carel W le Roux et al. LANCET
- Perceptions of Barriers to Effective Obesity Care: Results from the National ACTION Study
- (2017) Lee M. Kaplan et al. Obesity
- Coadministration of lorcaserin and phentermine for weight management: A 12-week, randomized, pilot safety study
- (2017) Steven R. Smith et al. Obesity
- A Proposal of the European Association for the Study of Obesity to Improve the ICD-11 Diagnostic Criteria for Obesity Based on the Three Dimensions Etiology, Degree of Adiposity and Health Risk
- (2017) Johannes Hebebrand et al. Obesity Facts
- Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency
- (2017) Tinh-Hai Collet et al. Molecular Metabolism
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY
- (2016) W. Timothy Garvey et al. Endocrine Practice
- Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist
- (2016) Peter Kühnen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial
- (2016) Lancet Diabetes & Endocrinology
- Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From aDiabetes CareEditors’ Expert Forum
- (2015) William T. Cefalu et al. DIABETES CARE
- Association Between Bariatric Surgery and Long-term Survival
- (2015) David E. Arterburn et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the 2014 Advanced Framework for a New Diagnosis of Obesity as a Chronic Disease
- (2014) W. Garvey et al. Endocrine Practice
- Bariatric surgery and its impact on cardiovascular disease and mortality: A systematic review and meta-analysis
- (2014) Chun Shing Kwok et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- New Tools for Weight-Loss Therapy Enable a More Robust Medical Model for Obesity Treatment: Rationale for a Complications-Centric Approach
- (2013) W. Garvey Endocrine Practice
- Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study
- (2013) T A Wadden et al. INTERNATIONAL JOURNAL OF OBESITY
- Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults
- (2013) Louis J. Aronne et al. Obesity
- The progression of cardiometabolic disease: Validation of a new cardiometabolic disease staging system applicable to obesity
- (2013) Fangjian Guo et al. Obesity
- A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)
- (2013) Caroline M. Apovian et al. Obesity
- Long-Term Effect of Weight Loss on Obstructive Sleep Apnea Severity in Obese Patients with Type 2 Diabetes
- (2013) Samuel T. Kuna et al. SLEEP
- The defence of body weight: a physiological basis for weight regain after weight loss
- (2012) Priya Sumithran et al. CLINICAL SCIENCE
- American Association of Clinical Endocrinologists' Position Statement on Obesity and Obesity Medicine
- (2012) Jeffrey Mechanick et al. Endocrine Practice
- A Randomized, Double-Blind, Placebo-Controlled Study of an Oral, Extended-Release Formulation of Phentermine/Topiramate for the Treatment of Obstructive Sleep Apnea in Obese Adults
- (2012) David H. Winslow et al. SLEEP
- Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study
- (2011) W Timothy Garvey et al. AMERICAN JOURNAL OF CLINICAL NUTRITION
- Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes
- (2011) R. R. Wing et al. DIABETES CARE
- Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial
- (2011) Kishore M Gadde et al. LANCET
- Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)
- (2011) David B. Allison et al. Obesity
- Effect of a 12-Month Intensive Lifestyle Intervention on Hepatic Steatosis in Adults With Type 2 Diabetes
- (2010) M. Lazo et al. DIABETES CARE
- Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- (2010) Frank L Greenway et al. LANCET
- Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR-BMOD Trial
- (2010) Thomas A. Wadden et al. Obesity
- A proposed clinical staging system for obesity
- (2009) A M Sharma et al. INTERNATIONAL JOURNAL OF OBESITY
- Effect of Bariatric Surgery on Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis
- (2008) Rajasekhara R. Mummadi et al. Clinical Gastroenterology and Hepatology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started